-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Under normal circumstances, the small intestine secretes incretin after a meal, which promotes postprandial insulin secretion and lowers
blood sugar .
Patients with type 2 diabetes have significantly reduced incretin effects and impaired postprandial glucose tolerance
low blood sugar diabetes
Studies have shown that DPP-4 inhibitors, as a new oral hypoglycemic drug, have a glucose concentration-dependent hypoglycemic mechanism, which can improve β-cells and protect the kidneys
.
In terms of side effects, it does not induce hypoglycemia and does not cause weight gain and intestinal side effects
Studies have shown that DPP-4 inhibitors, as a new oral hypoglycemic drug, have a glucose concentration-dependent hypoglycemic mechanism, which can improve β-cells and protect the kidneys
Current studies suggest that DPP4 inhibitors may have off-target cardiovascular effects
.
Among them, DPP4 inhibition attenuated the hypotensive effect of acute ACEI (angiotensin-converting enzyme) and increased norepinephrine concentrations
Blood vessel
The study enrolled 106 adults with type 2 diabetes and high blood pressure , 100 of whom received the intervention
.
Subjects were randomly assigned to one of 3 blood pressure groups: ramipril, valsartan, or amlodipine for 15 weeks and received 3 one-week crossover treatments in random order: placebo + placebo, Sitagliptin + placebo, sitagliptin + aprepitant, with a 4-week washout
hypertension
Results showed that DPP4 inhibition increased norepinephrine concentrations but not blood pressure during ramipril
.
Aprepitant, an NK1 (substance P) receptor blocker, reduces orthostatic heart rate during blockade of the renin-angiotensin-aldosterone system with ramipril or valsartan
Results showed that DPP4 inhibition increased norepinephrine concentrations but not blood pressure during ramipril
Effects of DPP4 inhibitors on the renin-angiotensin-aldosterone system
Effects of DPP4 inhibitors on the renin-angiotensin-aldosterone systemTaken together, increased catecholamines may lead to cardiovascular complications in patients prone to heart failure when an ACEI and a DPP4 inhibitor are administered concurrently
.
.
Taken together, increased catecholamines may lead to cardiovascular complications in patients prone to heart failure when an ACEI and a DPP4 inhibitor are administered concurrently
references:
DPP4 (Dipeptidyl Peptidase-4) Inhibition Increases Catecholamines Without Increasing Blood Pressure During Sustained ACE (Angiotensin-Converting Enzyme) Inhibitor Treatment.
DPP4 (Dipeptidyl Peptidase-4) Inhibition Increases Catecholamines Without Increasing Blood Pressure During Sustained ACE (Angiotensin-Converting Enzyme) Inhibitor Treatment.
https://doi.
org/10.
1161/HYPERTENSIONAHA.
121.
18348 Leave a comment here
